Celltrion: "Remsima SC and Zymfentra Are Now Within Reach of 1 Trillion Won in Annual Sales"
Combined sales reach 456.2 billion won in H1
Growth continues amid expanded prescriptions in Europe and rising Zymfentra sales in the U.S.
Pursuing entry into new markets, including Japan and Central and South America
Celltrion's subcutaneous infliximab formulation 'Remsima SC' and its US-sold counterpart 'Zymfentra' are expected to achieve annual sales of 1 trillion won.
On August 27, Celltrion announced that global sales of Remsima SC in the first half of this year totaled 356.7 billion won, while US sales of Zymfentra reached 99.5 billion won. Combined, the products recorded sales of 456.2 billion won. Year-over-year growth rates stood at 20.3% for Remsima SC and 176.4% for Zymfentra, respectively.
Celltrion plans to make the Remsima SC product lineup its second product—after Remsima itself—to achieve 1 trillion won in annual sales. This will be driven by expanding prescriptions in existing markets, increasing supply in the second half of the year, and entering new markets..
The growth of Remsima SC is attributed to the effective 'dual formulation' strategy, where both Remsima (the intravenous infliximab formulation) and Remsima SC (the subcutaneous form) are supplied together. Medical professionals can select either the IV formulation, administered in hospitals, or the SC formulation, which patients can self-inject, depending on the patient's condition and treatment environment.
Leveraging this competitive edge in formulations, Celltrion is strengthening the synergy between products by enabling patients who switch from competing infliximab products to Remsima to continue their maintenance therapy with Remsima SC.
The steadily growing European infliximab market is also expanding the foundation for Remsima SC's growth. According to IQVIA, the European infliximab market has grown at an average annual rate of approximately 9% from 2019 to 2024.
Sales of Zymfentra in the US are also gaining momentum. Unlike conventional infliximab therapy, which requires hospital visits for IV administration, Zymfentra can be self-injected by patients at their chosen location according to prescription, significantly improving treatment convenience.
In the US, Celltrion is expanding customized marketing activities targeting healthcare professionals and patients by leveraging its insurance reimbursement infrastructure and distribution network. Additional initiatives to boost product awareness and prescription preference are underway, with the goal of sustaining growth in Zymfentra's prescriptions and sales.
Alongside growth in existing markets, Celltrion is also pursuing new market entries for Remsima SC. The company plans to launch Remsima SC in Japan, a key pharmaceutical market in Asia, in 2027. In Central and South America, it will gradually expand sales regions in line with country-specific approvals and market conditions.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion official stated, "The Remsima SC product lineup is experiencing diversified growth, driven by stable expansion in Europe and significant increases in US Zymfentra sales. We will continue our efforts to expand prescriptions in established markets and launch in new regions such as Japan and Central and South America to develop the Remsima SC lineup into a pharmaceutical product with annual sales of 1 trillion won."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.